CYP46A1 and myeloid sarcoma: Cholesterol, its metabolites, and the enzyme CYP46A1, responsible for cholesterol turnover in the brain, are considered important fluid and imaging biomarkers, as well as potential treatment targets, for a wide range of neurological conditions including MS [2, 3, 4, 5, 6, 7, 8].